Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067243 | 0.95 | OPRD1 (0.54) | NTSR1OPRD1NTSR2F2OPRM1 | |
| SCHEMBL29800900 | 0.93 | NTSR1 (0.48) | NTSR1OPRD1NTSR2MAPK8MAPK9 | |
| SCHEMBL31067241 | 0.91 | NTSR1 (0.55) | NTSR1OPRD1NTSR2F2OPRM1 | |
| SCHEMBL29569246 | 0.89 | NTSR1 (0.44) | NTSR1OPRD1NTSR2MAPK8MAPK9 | |
| SCHEMBL30918791 | 0.89 | OPRD1 (0.55) | OPRD1F2OPRM1 | |
| SCHEMBL29801041 | 0.87 | OPRM1 (0.55) | NTSR1OPRD1OPRM1 | |
| SCHEMBL28062744 | 0.87 | OPRD1 (0.58) | NTSR1OPRD1MAPK8MAPK9MAPK10 | |
| SCHEMBL29801129 | 0.86 | PTPN1 (0.45) | NTSR1OPRD1F2PTPN1 | |
| SCHEMBL29904119 | 0.86 | MAGI3 (0.52) | NTSR1PTPN1 | |
| SCHEMBL31226869 | 0.86 | NTSR1 (0.60) | NTSR1OPRD1NTSR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109422799-B | Docetaxel liver cancer-resisting targeted prodrug and medicinal application thereof | 复旦大学 | 2022-07-29 | — | — | CN | disclosed |